What is the primary reason for the decrease in net income/increase in net loss compared to the prior year?

The primary reason for the significant decrease in net income (or increase in net loss) for the first six months of 2005 compared to the same period in 2004 is a substantial reduction in revenues. This is mainly due to lower revenues from the collaboration with sanofi-aventis Group related to the VEGF Trap and the absence of revenues from the prior collaboration with Novartis Pharma AG, which concluded in 2004.

How is Regeneron's liquidity and cash position?

Regeneron's liquidity appears strong. As of June 30, 2005, the company reported cash and cash equivalents of $145.2 million, an increase from $95.2 million at December 31, 2004. Despite the net loss, operating activities generated positive cash flow of $4.5 million in the first half of 2005, supported by milestone payments and reimbursements from collaborators. Management expects current capital resources to fund operations through at least mid-2007.

What is the company's strategy regarding its product pipeline and research & development?

Regeneron is strategically focused on the development of its key product candidates: the VEGF Trap for oncology and eye diseases, and the IL-1 Trap for various inflammatory conditions such as rheumatoid arthritis and CAPS. The company is heavily investing in research and development, including clinical trials for these candidates, and also maintains research programs in other disease areas. They are leveraging their technology platforms to discover and develop new therapeutics.

What is the impact of the new stock-based compensation accounting standard adopted in 2005?

Effective January 1, 2005, Regeneron adopted the fair value method for stock-based employee compensation (SFAS 123). This means the company now recognizes expense based on the fair value of stock options and awards over their vesting period. This change has led to increased non-cash stock-based compensation expense being recognized in operating expenses, negatively impacting reported net income and earnings per share, particularly when comparing periods before and after adoption.

REGN 10-Q Quarterly Report Q2 FY2005 — Revenue, Net Income, EPS

Summary

Regeneron Pharmaceuticals, Inc. reported a net loss of $31.1 million for the six months ended June 30, 2005, a significant decline from the $49.9 million net income reported in the same period of 2004. This shift is largely attributable to reduced revenues from key collaborations, particularly with sanofi-aventis Group and the absence of revenue from Novartis Pharma AG. The company is heavily investing in research and development, with a focus on its VEGF Trap and IL-1 Trap product candidates for various indications including oncology, eye diseases, and inflammatory conditions. Despite the net loss, Regeneron's cash position remains strong, with cash and cash equivalents of $145.2 million as of June 30, 2005, up from $95.2 million at the end of 2004. This increase is partly due to milestone payments and reimbursements from collaborators. The company anticipates its current capital resources will sustain operations through mid-2007, but acknowledges the ongoing need for substantial funding for its extensive development pipeline.

Key Highlights

1Net loss of $31.1 million for the first six months of 2005, compared to net income of $49.9 million in the prior year period.
2Total revenue decreased to $32.6 million for the first six months of 2005 from $90.4 million in the same period of 2004, primarily due to lower collaboration revenues from sanofi-aventis and the conclusion of the Novartis collaboration.
3Cash and cash equivalents increased to $145.2 million as of June 30, 2005, from $95.2 million at December 31, 2004.
4Significant ongoing investment in research and development, with a focus on VEGF Trap (oncology and eye diseases) and IL-1 Trap (rheumatoid arthritis, CAPS, osteoarthritis).
5Adopted the fair value method for stock-based compensation effective January 1, 2005, resulting in increased reported expenses.
6Entered into a settlement for a class action lawsuit, with no payment required from the company, as the primary insurance carrier agreed to cover the immaterial settlement amount.
7Expects current capital resources to be sufficient through at least mid-2007, but acknowledges the potential need for additional financing.

REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q2 Ended Jun 30, 2005

Summary

Key Highlights

Frequently Asked Questions